GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avidity Biosciences Inc (NAS:RNA) » Definitions » Shares Outstanding (Diluted Average)

RNA (Avidity Biosciences) Shares Outstanding (Diluted Average) : 123.38 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Avidity Biosciences Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Avidity Biosciences's average diluted shares outstanding for the quarter that ended in Sep. 2024 was 123.38 Mil.


Avidity Biosciences Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Avidity Biosciences's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avidity Biosciences Shares Outstanding (Diluted Average) Chart

Avidity Biosciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Diluted Average)
Get a 7-Day Free Trial 20.68 21.66 41.43 52.16 73.01

Avidity Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.10 76.09 87.21 106.93 123.38

Avidity Biosciences Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Avidity Biosciences  (NAS:RNA) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Avidity Biosciences Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Avidity Biosciences's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Avidity Biosciences Business Description

Industry
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Executives
Arthur A Levin officer: Chief Scientific Officer 1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Teresa Mccarthy officer: Chief Human Resources Officer 10975 N TORREY PINES RD #150, LA JOLLA CA 92037
Michael F Maclean officer: Chief Financial Officer 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tamar Thompson director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
W. Michael Flanagan officer: Chief Technical Officer C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Sarah Boyce director, officer: President and CEO C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Eric Mosbrooker director C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jean Jinsun Kim director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Jae B. Kim officer: Chief Medical Officer C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Kaye Edward M. Md director 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen director, 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Roderick Wong director, 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014